Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

36.7%

84 terminated/withdrawn out of 229 trials

Success Rate

54.6%

-31.9% vs industry average

Late-Stage Pipeline

7 trials in Phase 3/4

Results Transparency

71%

72 of 101 completed trials have results

Key Signals

30 recruiting72 with results70 terminated14 withdrawn

Enrollment Performance

Analytics

Phase 2

62(36.3%)

Phase 1

47(27.5%)

N/A

45(26.3%)

Early Phase 1

10(5.8%)

Phase 3

4(2.3%)

Phase 4

3(1.8%)

171Total

Phase 2(62)

Phase 1(47)

N/A(45)

Early Phase 1(10)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (229)

Showing 20 of 229 trials

NCT07460765Phase 1Recruiting

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Role: lead

NCT06819228Phase 1Recruiting

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Role: lead

NCT07188896Phase 2Recruiting

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Role: collaborator

NCT07673367Phase 2Not Yet Recruiting

Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Role: lead

NCT07210632Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Role: collaborator

NCT06016855Phase 4Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Role: lead

NCT06399640Phase 1Recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Role: lead

NCT05770531Phase 2Recruiting

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Role: lead

NCT02493530Phase 1Completed

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Role: lead

NCT07217028Phase 1Recruiting

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Role: lead

NCT06828588Early Phase 1Recruiting

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Role: lead

NCT05747625Phase 1Recruiting

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT06915454Not ApplicableRecruiting

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Role: lead

NCT03181256Active Not Recruiting

Early Detection of Lung Cancer

Role: lead

NCT06074133Active Not Recruiting

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Role: lead

NCT03962647Early Phase 1Completed

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Role: lead

NCT05764395Phase 2Active Not Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Role: lead

NCT05361720Phase 2Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Role: lead

NCT00898313Recruiting

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Role: lead

NCT06638398Not ApplicableActive Not Recruiting

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

Role: lead